Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
@AnnieTyzak Eye issues? Never supported with strong evidence.
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
‏‎8.13 ألف‏
‏‎0‏
المحتوى الوارد في هذه الصفحة مُقدَّم من أطراف ثالثة. وما لم يُذكَر خلاف ذلك، فإن OKX ليست مُؤلِّفة المقالة (المقالات) المذكورة ولا تُطالِب بأي حقوق نشر وتأليف للمواد. المحتوى مٌقدَّم لأغراض إعلامية ولا يُمثِّل آراء OKX، وليس الغرض منه أن يكون تأييدًا من أي نوع، ولا يجب اعتباره مشورة استثمارية أو التماسًا لشراء الأصول الرقمية أو بيعها. إلى الحد الذي يُستخدَم فيه الذكاء الاصطناعي التوليدي لتقديم مُلخصَّات أو معلومات أخرى، قد يكون هذا المحتوى الناتج عن الذكاء الاصطناعي غير دقيق أو غير مُتسِق. من فضلك اقرأ المقالة ذات الصِلة بهذا الشأن لمزيدٍ من التفاصيل والمعلومات. OKX ليست مسؤولة عن المحتوى الوارد في مواقع الأطراف الثالثة. والاحتفاظ بالأصول الرقمية، بما في ذلك العملات المستقرة ورموز NFT، فيه درجة عالية من المخاطر وهو عُرضة للتقلُّب الشديد. وعليك التفكير جيِّدًا فيما إذا كان تداوُل الأصول الرقمية أو الاحتفاظ بها مناسبًا لك في ظل ظروفك المالية.